Marksans Pharma
MARKSANS · Pharma > Pharmaceuticals & Drugs · Chairman: Mark Saldanha · MD: Mark Saldanha · Listing date: Jan. 22, 2002 · Employees: 1138 · Mumbai · http://www.marksanspharma.com

Stock Price vs Company Growth
1d
3.0%
1w
3.1%
1m
17.0%
3m
57.9%
6m
38.9%
1y
2.1%
5y
24.8%
10y
19.9%
all
17.8%

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

₹ 255 3.0%
156
265
Company Overview

Sales
2,951 Cr
Growth: 12.2%
Profit after Tax
418 Cr
Growth: 16.0%
Mid Cap
11,544 Cr
P/E: 27.6x
Industry P/E: 31.3x
Fundamentals

Sales (Cr) ₹ 2,951
Growth 12.2%
EBITDA 20.4%
P/S 3.9x
Dividend 0.4%
P/E 27.6x
Book Value ₹ 66.7
PEG Ratio 2.3x
ROE 15.3%
P/B 3.8x
Shareholding Pattern

Institutions
Promoters
Mark Saldanha
48.25 %
Others
Mukul Mahavir Prasad Agrawal
1.47 %
Increase    Decrease    No change
Company Profile Detailed

The company is a globally-trusted, customer-centric pharmaceutical company with a strong presence in regulated markets. The company specialises in developing and manufacturing & distributing both over-the-counter (OTC) and prescription (Rx) drugs, aligning its offerings with the evolving needs of patients and healthcare providers across the world.
Investors (49)
Followers (8)